Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -W-
05.08.2024 22:10:21

Biomarin Pharmaceutical Inc. Q2 Profit Increases, Beats Estimates

(RTTNews) - Biomarin Pharmaceutical Inc. (BMRN) announced earnings for its second quarter that increased from the same period last year and beat the Street estimates.

The company's earnings totaled $107.174 million, or $0.55 per share. This compares with $56.040 million, or $0.29 per share, in last year's second quarter.

Excluding items, Biomarin Pharmaceutical Inc. reported adjusted earnings of $188.9 million or $0.96 per share for the period.

Analysts on average had expected the company to earn $0.35 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 19.6% to $712.029 million from $595.275 million last year.

Biomarin Pharmaceutical Inc. earnings at a glance (GAAP) :

-Earnings (Q2): $107.174 Mln. vs. $56.040 Mln. last year. -EPS (Q2): $0.55 vs. $0.29 last year. -Revenue (Q2): $712.029 Mln vs. $595.275 Mln last year.

-Guidance: Full year EPS guidance: $3.10 - $3.25 Full year revenue guidance: $2,750 - $2,825 Mln

Analysen zu Biomarin Pharmaceutical Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Biomarin Pharmaceutical Inc. 58,90 -0,64% Biomarin Pharmaceutical Inc.